AI Digital Therapeutics Designer Interview Questions

A strong answer distinguishes DTx by its evidence-based clinical validation, regulatory pathway (often FDA-cleared), and therapeutic intent to treat or manage a specific disease.

Cover the cognitive model (thoughts → feelings → behaviors), structured exercises like thought records, and how digital tools can deliver CBT modules adaptively.

Explain FHIR as a modern healthcare data interoperability standard and discuss how DTx products use it to receive patient context and report outcomes.

Cover informed consent for AI-driven care, algorithmic bias affecting treatment equity, and the need for human clinician escalation paths.

Discuss encryption at rest and in transit, access controls, audit logging, business associate agreements, and minimum necessary data principles.

Discuss time-series mood data modeling, multi-armed bandit or contextual bandit approaches for content selection, and the role of clinical protocol guardrails.

Explain the SaMD risk categorization matrix based on healthcare situation and significance of information provided, and map an insomnia DTx to the appropriate class.

Cover vector database storage of curated clinical content, embedding-based retrieval, prompt construction with patient context, and hallucination mitigation strategies.

Discuss clinical endpoints (abstinence rates, relapse frequency), engagement metrics (session completion, streak length, time-in-app), and PROs (patient-reported outcomes).

Example: evidence-based CBT protocols require structured homework completion, but high friction leads to dropout - discuss adaptive pacing, gamification with clinical guardrails.

Discuss fairness metrics (equalized odds, demographic parity), stratified performance analysis, bias sources in training data, and mitigation techniques.

CDS tools that support (not replace) clinician judgment may be exempt from device regulation under 21st Century Cures Act §3060; DTx products are intended to treat and are regulated as devices.

Cover intent detection for self-harm or crisis language, tiered escalation (automated coping → human clinician → emergency services), and fail-safe defaults.

Discuss micro-randomized trials, just-in-time adaptive interventions (JITAIs), and how RL models learn optimal action policies from longitudinal patient interaction data.

Discuss RCT evidence demonstrating clinical outcomes, cost-effectiveness analyses, CPT/HCPCS coding pathways, and value-based contracting models.

Cover federated averaging, differential privacy guarantees, communication efficiency, handling non-IID clinical data distributions, and aggregation server security.

Discuss multi-modal fusion strategies (early, late, hybrid), temporal alignment of heterogeneous data streams, and privacy-preserving feature extraction.

Discuss cultural psychology factors in treatment engagement, localization beyond translation (stigma framing, collectivist vs. individualist motivation), and re-running pilot studies with culturally adapted protocols.

Discuss propensity score matching, instrumental variables, difference-in-differences, and the use of EHR-linked RWE data with proper confounder adjustment.

Cover model versioning and reproducibility, regression testing against clinical benchmarks, abstraction layers for model swapping, and regulatory implications of model changes as software updates.

Discuss automated safety classifiers, red-teaming for adversarial patient scenarios, clinical expert panel review using standardized rubrics (e.g., adapted MEMS or DISCERN), and continuous monitoring post-launch.

Cover grounding strategies (RAG with verified clinical sources), structured output constraints, sycophancy detection, and the tension between personalization and evidence-based treatment fidelity.

Discuss GAD-7 as primary endpoint, superiority vs. non-inferiority design, sham-app control groups, adaptive trial designs, and powering considerations for subgroup analyses.

Discuss MDR classification for SaMD, EU AI Act high-risk AI obligations (transparency, human oversight, data governance), conformity assessment, and the intersection with Notified Body review.

Cover feature engineering from raw sensor streams, validated against PHQ-9/GAD-7 ground truth, longitudinal modeling with missing data handling, and clinical validation requirements for passive monitoring.

Cover real-time NLP crisis detection, immediate in-app safety resources, automated alert to assigned clinician, documentation for incident review, and follow-up protocol.

Discuss adaptive dose-response optimization, engagement-driven retention improvements backed by data, network effects from anonymized learning across patient cohorts, and regulatory barriers to replication.

Cover immediate safety response (audit trail, patient notification, clinical review), root cause analysis (prompt injection, knowledge base error), implementation of medication disclaimers and topic-blocking, and post-incident monitoring.

Discuss minimal-click clinician dashboard, asynchronous review workflows, clear value proposition for clinicians (patient progress visibility, reduced no-shows), and phased rollout with champion clinicians.

Discuss simplified UI/UX, voice-first interaction mode, caregiver-assisted onboarding, adaptive complexity based on digital literacy assessment, and maintaining therapeutic protocol fidelity.

Discuss modular architecture separating regulated therapeutic components from general features, configuration-driven regulatory profiles, and shared evidence packages with jurisdiction-specific appendices.

Cover critical appraisal of their methodology, honest assessment of gaps in your product, rapid experimentation on improvements, transparent communication with stakeholders, and evidence-generation roadmap acceleration.

Discuss stratified model evaluation, targeted data augmentation or collection, culturally adapted feature engineering, transparent reporting of limitations, and prioritization framework for equity fixes.

Discuss behavioral nudging techniques, structured conversation flows that embed therapeutic exercises naturally, engagement vs. clinical outcome trade-off analysis, and A/B testing of conversational structure variants.

Discuss health economic modeling, QALY analysis, claims data linkage methodology, real-world cost offset measurement (ER visits, medication changes), and value-based contract structure with outcome guarantees.

Cover document ingestion and chunking, embedding generation (e.g., with BioBERT), vector database storage, retrieval with patient-context-aware ranking, prompt construction, LLM generation, output validation, and delivery pipeline.

Discuss MLflow or W&B for experiment logging, data versioning with DVC, model cards for documentation, reproducibility requirements, and audit trail generation for 21 CFR Part 11 compliance.

Cover curated therapeutic dialogue datasets, RLHF with clinical expert annotators, safety-specific fine-tuning with harmful output penalization, and evaluation via automated metrics plus clinical expert review.

Discuss state representation (mood, time, context), action set design (exercise types), reward signal definition (engagement + clinical improvement), Thompson sampling or LinUCB algorithms, and micro-randomized trial design for policy evaluation.

Cover PHI detection using NER models (e.g., Philter, Presidio), text anonymization pipelines, synthetic data generation as an alternative, data use agreements, and IRB considerations for secondary data use.

Discuss real-time output classifiers, red-team test suites, logging and flagging pipelines, human review queues, model rollback mechanisms, and integration with incident response workflows.

Cover feature engineering from session data (recency, frequency, duration), sequence modeling with RNNs or Transformers, survival analysis for time-to-dropout, and deploying the model to trigger re-engagement interventions.

Discuss curated content sources (clinical guidelines, peer-reviewed literature), editorial review workflow, version-controlled content repository, embedding refresh pipeline, and retrieval confidence thresholds that trigger human review.

Cover agent architecture with tool use (mood assessment, intervention library lookup, content retrieval), chain-of-thought prompting for clinical reasoning, guardrails at each step, and structured output for intervention delivery.

Discuss input distribution monitoring (PSI, KS tests), prediction drift detection, clinical outcome lag tracking, alerting thresholds, automated retraining pipelines with human validation gates, and A/B testing of updated models.

A strong answer demonstrates courage to push back, ability to articulate risks in business terms, and a collaborative approach to finding solutions that meet both safety and timeline needs.

Look for structured communication, use of analogies or visual aids, validation that the audience understood, and awareness of the different priorities each group holds.

A strong answer shows intellectual humility, willingness to change course based on evidence, and the ability to communicate revised conclusions to stakeholders without losing credibility.

Look for specific habits: reading key journals (npj Digital Medicine, JAMA Digital Health), attending DTA or DTx conferences, participating in professional communities, and structured learning commitments.

A strong answer demonstrates structured decision-making frameworks, stakeholder communication about uncertainty, risk mitigation planning, and post-decision review processes.